• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于癌症免疫治疗的人类原代自然杀伤细胞和T细胞的CRISPR基因编辑

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.

作者信息

Elmas Ezgi, Saljoughian Noushin, de Souza Fernandes Pereira Marcelo, Tullius Brian P, Sorathia Kinnari, Nakkula Robin J, Lee Dean A, Naeimi Kararoudi Meisam

机构信息

Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, United States.

Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States.

出版信息

Front Oncol. 2022 Apr 5;12:834002. doi: 10.3389/fonc.2022.834002. eCollection 2022.

DOI:10.3389/fonc.2022.834002
PMID:35449580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9016158/
Abstract

Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat cancers. Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing has become one of the most popular tools to enhance immune cell antitumor activity. In this review we highlight applications and practicability of CRISPR/Cas9 gene editing and engineering strategies for cancer immunotherapy. In addition, we have reviewed several approaches to study CRISPR off-target effects.

摘要

诸如T细胞和NK细胞等免疫细胞的抗肿瘤活性使其成为适应性癌症免疫治疗的理想治疗方案。增强它们对恶性肿瘤的细胞毒性作用并克服它们在肿瘤微环境(TME)中的抑制作用,可能会提高它们治疗癌症的疗效。成簇规律间隔短回文重复序列(CRISPR)基因组编辑已成为增强免疫细胞抗肿瘤活性的最流行工具之一。在本综述中,我们重点介绍了CRISPR/Cas9基因编辑及癌症免疫治疗工程策略的应用和实用性。此外,我们还综述了几种研究CRISPR脱靶效应的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/9016158/62f67fe89985/fonc-12-834002-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/9016158/67d88d3147a7/fonc-12-834002-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/9016158/62f67fe89985/fonc-12-834002-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/9016158/67d88d3147a7/fonc-12-834002-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/9016158/62f67fe89985/fonc-12-834002-g002.jpg

相似文献

1
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.用于癌症免疫治疗的人类原代自然杀伤细胞和T细胞的CRISPR基因编辑
Front Oncol. 2022 Apr 5;12:834002. doi: 10.3389/fonc.2022.834002. eCollection 2022.
2
Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.靶向基于 CRISPR/Cas9 的基因组编辑工具的免疫系统细胞重编程创新策略:癌症管理的新时代。
Int J Nanomedicine. 2023 Sep 29;18:5531-5559. doi: 10.2147/IJN.S424872. eCollection 2023.
3
Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.利用CRISPR-Cas9基因编辑系统治疗人类癌症和进行免疫治疗。
Clin Transl Immunology. 2021 Jun 22;10(6):e1286. doi: 10.1002/cti2.1286. eCollection 2021.
4
Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.利用 CRISPR/Cas9 进行 NK 细胞基因重编程以实现癌症免疫治疗
Immunology. 2019 Oct;158(2):63-69. doi: 10.1111/imm.13094. Epub 2019 Aug 14.
5
The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.CRISPR-Cas9 基因组编辑工具在癌症免疫治疗中的应用。
Brief Funct Genomics. 2019 Mar 22;18(2):129-132. doi: 10.1093/bfgp/ely011.
6
CRISPR, CAR-T, and NK: Current applications and future perspectives.CRISPR、嵌合抗原受体T细胞(CAR-T)和自然杀伤细胞(NK):当前应用与未来展望。
Genes Dis. 2023 Sep 19;11(4):101121. doi: 10.1016/j.gendis.2023.101121. eCollection 2024 Jul.
7
Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review.探索成簇规律间隔短回文重复序列-CRISPR相关蛋白9(CRISPR-Cas9)作为癌症治疗手段的研究:一项范围综述
Cureus. 2024 Jul 11;16(7):e64324. doi: 10.7759/cureus.64324. eCollection 2024 Jul.
8
CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.CRISPR/Cas9与嵌合抗原受体T细胞(CAR-T细胞),癌症免疫治疗中两项革命性技术的协作,癌症成功治疗指南。
Hum Immunol. 2018 Dec;79(12):876-882. doi: 10.1016/j.humimm.2018.09.007. Epub 2018 Sep 24.
9
CRISPR-Based Approaches for Cancer Immunotherapy.基于 CRISPR 的癌症免疫疗法。
Crit Rev Oncog. 2023;28(4):1-14. doi: 10.1615/CritRevOncog.2023048723.
10
Applications and advances of CRISPR-Cas9 in cancer immunotherapy.CRISPR-Cas9 在癌症免疫治疗中的应用与进展。
J Med Genet. 2019 Jan;56(1):4-9. doi: 10.1136/jmedgenet-2018-105422. Epub 2018 Jul 3.

引用本文的文献

1
HPV-driven cancers: a looming threat and the potential of CRISPR/Cas9 for targeted therapy.人乳头瘤病毒驱动的癌症:一个迫在眉睫的威胁以及CRISPR/Cas9用于靶向治疗的潜力
Virol J. 2025 May 22;22(1):156. doi: 10.1186/s12985-025-02783-x.
2
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.通过非病毒工程和高度多重碱基编辑提高CAR-NK细胞的精准度。
J Immunother Cancer. 2025 May 7;13(5):e009560. doi: 10.1136/jitc-2024-009560.
3
Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing.

本文引用的文献

1
Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.使用 CRISPR 和 AAV 优化和验证 CAR 转导到人类原代 NK 细胞。
Cell Rep Methods. 2022 Jun 13;2(6):100236. doi: 10.1016/j.crmeth.2022.100236. eCollection 2022 Jun 20.
2
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.嵌合抗原受体T细胞疗法与小儿肉瘤中的免疫抑制肿瘤微环境
Cancers (Basel). 2021 Sep 20;13(18):4704. doi: 10.3390/cancers13184704.
3
Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
探索用于治疗性基因组编辑的先进CRISPR递送技术。
Small Sci. 2024 Jul 25;4(10):2400192. doi: 10.1002/smsc.202400192. eCollection 2024 Oct.
4
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.解锁CAR-NK细胞疗法现有瓶颈的新型基因操作方法。
Front Cell Dev Biol. 2025 Feb 11;12:1511931. doi: 10.3389/fcell.2024.1511931. eCollection 2024.
5
CRISPR-Cas9 in basic and translational aspects of cancer therapy.CRISPR-Cas9在癌症治疗的基础和转化研究方面
Bioimpacts. 2024;14(6):30087. doi: 10.34172/bi.2024.30087. Epub 2024 Mar 10.
6
Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.非病毒方法在 CAR-NK 细胞工程中的应用:连接自然杀伤细胞生物学和基因传递。
J Nanobiotechnology. 2024 Sep 10;22(1):552. doi: 10.1186/s12951-024-02746-4.
7
Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions.嵌合抗原受体自然杀伤细胞(CAR-NK)疗法在肿瘤免疫治疗中的新兴作用:现状与未来方向。
Cell Death Discov. 2024 Jul 10;10(1):318. doi: 10.1038/s41420-024-02077-1.
8
Natural killer cell memory: challenges and opportunities for cancer immunotherapy.自然杀伤细胞记忆:癌症免疫治疗的挑战与机遇。
Cancer Biol Ther. 2024 Dec 31;25(1):2376410. doi: 10.1080/15384047.2024.2376410. Epub 2024 Jul 10.
9
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment.用于肿瘤治疗的基于生物材料的CRISPR/Cas9递送系统
Biomater Res. 2024 Apr 30;28:0023. doi: 10.34133/bmr.0023. eCollection 2024.
10
CRISPR, CAR-T, and NK: Current applications and future perspectives.CRISPR、嵌合抗原受体T细胞(CAR-T)和自然杀伤细胞(NK):当前应用与未来展望。
Genes Dis. 2023 Sep 19;11(4):101121. doi: 10.1016/j.gendis.2023.101121. eCollection 2024 Jul.
利用 CRISPR/Cas9 技术进行 NK 和 T 细胞免疫治疗的基因工程:意义和挑战。
Cell Immunol. 2021 Nov;369:104436. doi: 10.1016/j.cellimm.2021.104436. Epub 2021 Sep 1.
4
Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy.靶向 T 细胞受体基因编辑为免疫治疗提供可预测的 T 细胞产物功能。
Cell Rep Med. 2021 Aug 17;2(8):100374. doi: 10.1016/j.xcrm.2021.100374.
5
Nonviral genome engineering of natural killer cells.自然杀伤细胞的非病毒基因组工程。
Stem Cell Res Ther. 2021 Jun 16;12(1):350. doi: 10.1186/s13287-021-02406-6.
6
CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.CRISPR/Cas9基因编辑在癌症免疫治疗中的应用:推动当前癌症治疗的变革并探索更多可能
Front Cell Dev Biol. 2021 May 20;9:674467. doi: 10.3389/fcell.2021.674467. eCollection 2021.
7
Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells.嵌合抗原受体 T 细胞治疗后的移植物抗宿主病风险:T 细胞的截然相反。
Br J Haematol. 2021 Dec;195(5):660-668. doi: 10.1111/bjh.17544. Epub 2021 May 25.
8
CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.CRISPR-Cas9 介导的人自然杀伤细胞 TIM3 基因敲除增强对人神经胶质瘤细胞的生长抑制作用。
Int J Mol Sci. 2021 Mar 28;22(7):3489. doi: 10.3390/ijms22073489.
9
Protocol for Isolation, Stimulation and Functional Profiling of Primary and iPSC-derived Human NK Cells.原代及诱导多能干细胞衍生的人自然杀伤细胞的分离、刺激及功能分析方案
Bio Protoc. 2020 Dec 5;10(23):e3845. doi: 10.21769/BioProtoc.3845.
10
Drug target validation in primary human natural killer cells using CRISPR RNP.利用 CRISPR RNP 在原代人自然杀伤细胞中进行药物靶标验证。
J Leukoc Biol. 2020 Oct;108(4):1397-1408. doi: 10.1002/JLB.2MA0620-074R. Epub 2020 Jul 17.